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Abstract
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus and commonly classified as a
Th2-type allergy. Major advances in our understanding of the EoE pathophysiology have recently been made, but
clinicians struggle with highly unpredictable therapy responses indicative of phenotypic diversity within the patient
population. Here, we summarize evidences for the existence of EoE subpopulations based on diverse inflammatory
characteristics of the esophageal tissue in EoE. Additionally, clinical characteristics of EoE patients support the
concept of disease subtypes. We conclude that clinical and experimental evidences indicate that EoE is an umbrella
term for conditions that are unified by esophageal eosinophilia but that several disease subgroups with various
inflammatory esophageal patterns and/or different clinical features exist. We further discuss strategies to study the
pathophysiologic differences as observed in EoE patients in murine experimental EoE. Going forward, models of EoE
that faithfully mimic EoE subentities as defined in humans will be essential because mechanistic studies on triggers
which regulate the onset of diverse EoE subpopulations are not feasible in patients. Understanding how and why
different EoE phenotypes develop will be a first and fundamental step to establish strategies that integrate
individual variations of the EoE pathology into personalized therapy.
Background
The large number of recent reviews on eosinophilic
esophagitis (EoE) illustrates the importance of research
on this disease and underlines the great interest that al-
lergists, immunologists, and gastroenterologists have in
this condition. Several of the world-leading experts, in-
cluding (in alphabetical order) Drs. Aceves, Cianferoni,
Dellon, Furuta, Liacouras, Oyoshi, Rothenberg, and
Spergel, have recently provided detailed overviews on
the state of the art in EoE research [1–12]. To avoid re-
dundancy, we will only briefly summarize the diagnostic
approaches to identify EoE and the general features of
EoE pathology as we feel is necessary to facilitate the
subsequent discussion on emerging evidences for the ex-
istence of EoE subpopulations.
EoE is classified as a primary eosinophilic gastrointes-
tinal disorder (EGID) [13]. EGIDs constitute a heteroge-
neous group of diseases that, in addition to EoE, include
eosinophilic gastritis, eosinophilic gastroenteritis, eo-
sinophilic enteritis, and eosinophilic colitis. The unifying
hallmark and diagnostic marker of all EGIDs is an
eosinophil-rich inflammatory infiltrate of the affected
mucosa. The etiology of EGIDs is generally not well
understood. Tissue eosinophilia is typically considered
to be of unknown origin, but the pathogenesis of all
EGIDs appears to involve a complex interplay of genetic
predisposition, exposure to food, and/or environmental
allergens and Th2-type activation of the immune system
[14, 15]. In this review, we focus on EoE because it is
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currently the most commonly diagnosed EGID [13], with
a prevalence of 0.5–1 case/1000 persons and an inci-
dence of approximately 1 new case per 10,000 persons
per year [16], and is therefore the most extensively stud-
ied among the different varieties of EGIDs.
Pathophysiological characteristics of EoE
Diagnostic criteria
EoE is a clinicopathological disease. Quantification of
esophageal tissue eosinophils combined with assessment
of clinical symptomatology suggestive of esophageal dys-
function remains the gold standard in identifying pa-
tients with EoE [9, 17, 18]. The established histological
standard for diagnosing EoE is the presence of esopha-
gitis as characterized by >15 eosinophils per high power
field in esophageal mucosal biopsies following adequate
proton pump inhibitor therapy [17, 19]. EoE is defined
as isolated to the esophagus, and all other recognized
causes of esophageal eosinophilia must be ruled out
prior to diagnosis. It is well acknowledged that this
standard diagnostic approach by symptomatology and
histology is not only an invasive diagnostic method, as
esophageal biopsies are required, but also suffers from
poor specificity [20, 21]. Esophageal eosinophilia can be
found in other gastrointestinal (GI) disorders, and clin-
ical symptoms associated with EoE are often non-
specific, especially in young children [17, 19, 22–27].
In daily practice, distinguishing between EoE and reflux-
associated eosinophil infiltration of the esophagus as seen
in gastroesophageal reflux disease (GERD) remains par-
ticularly difficult, especially since the recent recognition of
a new entity: PPI-responsive esophageal eosinophilia (PPI-
REE). PPI-REE has similar clinicopathological characteris-
tics to EoE but resolves following high-dose PPI therapy
[7, 28–30]. GERD and EoE are not mutually exclusive,
and the relationship between GERD, EoE, and PPI-REE is
complex and not yet fully understood [31, 32]. In contrast
to GERD, EoE pathology appears to be strongly allergen-
driven. The comorbidity of allergic diseases ranges from
42 to 93 % in pediatric and 28–86 % in adult EoE patients,
which is significantly higher than in GERD patients or the
general population [30, 33–36].
Elevated serum IgE is found and used to identify
allergen-sensitized EoE individuals that suffer from an
IgE-mediated/allergen-driven disease phenotype. How-
ever, up to 50 % of EoE patients have normal serum IgE
levels and, as defined by consensus using standard
serum diagnostic approach, show no evidence for aller-
gic sensitization in serum. In a conclusive opinion piece,
it was recently argued that the pathogenesis of EoE is ra-
ther distinct from IgE-mediated food allergy [37]. The
authors make the point that eosinophilic inflammation
appears to be largely independent of IgE although food
has been recognized as a trigger factor of EoE. Despite
this recent review, common consensus is that, irrespect-
ive of the frequent absence of an allergic serum pheno-
type, EoE is classified as a Th2-type allergic disease
because of its inflammatory esophageal mRNA pattern
[19, 25, 38–41]. EoE was recently reviewed in detail from
the perspective of the allergist [42]. How various allergic
comorbidities potentially influence the EoE pathophysi-
ology will be an important topic to study. The question
as to whether EoE exists as an independent allergic/
atopic disease or is most frequently found as a secondary
manifestation in addition to another allergy needs to be
addressed in large, ideally multicenter, cohort studies.
Such studies will address important gaps in our under-
standing of the interplay of allergic conditions, which is
commonly referred to as the atopic march. In this con-
text, a recent publication demonstrated that EoE that
develops in the context of skin sensitization has very
unique features [43]. The type of EoE that develops after
allergic sensitization at the skin appears to be critically
mediated through the IL-33-ST2-basophil axis. This ob-
servation indicates that interference with this immune
modulatory axis might provide another opportunity for
individualized therapy of EoE provided that the finding
can be confirmed in other human EoE cohorts.
Treatment strategies
Clinicians treat EoE to reduce, or ideally resolve, esopha-
geal inflammation and to resolve symptoms. The most
commonly used therapeutic strategies for EoE are
proton-pump inhibitors, which are also important in the
diagnostic phase; topical corticosteroids, most often in
the form of swallowed fluticasone or liquid budesonide;
and/or dietary interventions. Several dietary strategies
are used, such as the six-food elimination diet, targeted
food elimination based off allergy testing, and elemental
diet therapy. Dilatation of esophageal strictures is also a
treatment strategy used to relieve EoE associated symp-
toms, such as dysphagia; however, it has no effect on in-
flammation [9]. The reported response rates to either
dietary interventions or topical steroids vary greatly from
50 % to >90 %, with the most often reported response
rate for commonly used dietary interventions and local
steroids being around 70 %. The highest response rates
are achieved by treatment with elemental diets; however,
this therapy is associated with high costs and low com-
pliance due to unpleasant taste [1, 9, 18, 22, 27, 44–50].
Even though there are studies that have shown benefits
from dietary therapy in adults, the therapeutic success of
dietary intervention for adult EoE is still debated
amongst experts [51].
Evidences for EoE subpopulations
Generally, it is important to stress that the concept of
differential disease subphenotypes and subgroups is not
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new to allergy research. For asthma, the most common
allergic disease, disease subtypes and individualized ther-
apy have, in fact, already been integrated in clinical prac-
tice and are known to be beneficial in guiding therapy
[52–54]. Basic research strategies have also been estab-
lished which model different asthma phenotypes and
mimic individual patient subpopulations [55]. Little at-
tention has been paid to EoE subtypes in clinical practice
so far, and basic research on EoE is only starting to inte-
grate the idea of EoE subtypes into experimental strat-
egies to understand EoE pathophysiology.
EoE patients cluster in subpopulations based on age and
clinical characteristics
Clinical presentation of EoE is highly age dependent. In-
fants tend to suffer from feeding difficulties and failure to
thrive. Children typically experience abdominal pain, nau-
sea, vomiting, and heartburn, whereas adolescents and
adults tend to present with dysphagia and episodes of food
impaction [1, 56]. Recently, new manuscripts describing
the adult onset of EoE have been published [26, 57, 58].
The comparative analysis of the roles of IgE and IgG4 in
adult EoE showed elevated serum levels of IgG4 with
food-specificity in adult EoE patients and a 45-fold in-
crease in IgG4 in homogenates of esophageal specimens
from adult EoE patients over controls. In support of the
IgE-independence of the adult EoE, no effect of omalizu-
mab, the most commonly used IgE-blocking therapy, was
observed [57]. Combined, these results indicate that adult
EoE might be IgG4-mediated rather than an IgE-mediated
allergy and, therefore, an EoE subpopulation in itself. It is,
of course, equally possible that the interplay between
antigen-specific IgG4 and IgE signals differentially shapes
adult EoE on the cellular level. The topic of IgG4 and IgE
in fuelling human allergic diseases was recently discussed
in detail and the nature of EoE as a ‘modified Th2-type’
disease was put forward [59]. However, mechanistic expla-
nations remain speculative in the absence of experimental
data on the topic.
Proton pump inhibitor-responsive esophageal eosino-
philia (PPI-REE) has recently been described [60] and
may represent another subtype of EoE. PPI-REE has
similar clinicopathological features to EoE, is also an al-
lergic disease, and presents with Th2-associated charac-
teristics comparable to EoE. Furthermore, the molecular
transcriptome of PPI-REE and EoE show significant
overlap. Current consensus suggests that PPI-REE and
EoE have a common pathogenesis and that PPI-REE
might constitute a subgroup of EoE [29, 61].
Another recently described phenotype of EoE consists
of EoE patients with an extreme narrow-caliber esopha-
gus. This patient group is characterized by a longer
symptom duration and a disease phenotype that is rather
refractory to steroid treatment [61].
EoE patients and comorbidities
EoE is more prevalent in patients suffering from other dis-
orders. For example, an association between EoE and ce-
liac disease has been suggested. However, contradicting
reports are found in the literature, and no mechanistic
studies have been performed [62–64]. Additionally, several
case reports and case series found a higher prevalence of
EoE in children with esophageal atresia [65–68]. Microde-
letions encompassing the Forkhead box (FOX) transcrip-
tion factor gene cluster have been shown to be associated
with esophageal atresia. Mouse studies have shown that
binding sites for Foxf1, one of the encoded proteins of the
FOX gene cluster, include the promoter region of genes
for inflammation, such as eotaxin. The expression of
eotaxin-3 is known to be increased in patients with EoE.
In combination, these results led to the hypothesis that
mutations in the FOX gene cluster play a role in the devel-
opment of esophageal atresia and EoE [64, 69]. Finally, an
elevated prevalence of EoE in patients with inherited con-
nective tissue diseases (CTDs), particularly those associ-
ated with hypermobility, has been described [7, 64, 70]. It
has been proposed that these patients represent a subpop-
ulation, referred to as EoE-CTD, with specific clinical
characteristics such as lower BMI and an elevated risk of
extra-esophageal eosinophilic gastrointestinal disease. In-
creased TGF-β signaling has been proposed as a molecu-
lar connection between EoE and CTDs [70]. Additionally,
association of EoE has been reported with celiac disease in
the pediatric population and celiac patients with active
disease [62, 71].
EoE patients cluster in subpopulations based on their
esophageal inflammatory mRNA pattern
Esophageal tissue inflammation is described to be highly
variable within the EoE patient group [7, 24]. Our research
group recently confirmed this observation with multiplexed
mRNA pattern analysis on esophageal biopsies [72] and
classical mRNA pattern studies with qRT-PCR [73, 74]. Im-
portantly, we discovered that EoE patients cluster in sub-
groups based on their mRNA expression profile, publishing
three research articles in which we described EoE subpopu-
lations with distinct inflammatory tissue characteristics
[72–74]. The first group, which we here refer to as LTC4S-
EoE, is characterized by a more pronounced esophageal
Th2-type inflammatory profile including TSLP and is typi-
fied by high expression of leukotriene C4 synthase (LTC4S,
[74]). Leukotrienes are known to actively contribute to al-
lergic inflammation. Interestingly, esophageal levels of
cysteinyl leukotrienes have been described not to differenti-
ate EoE patients from controls [17, 38], and the literature
on the effect of leukotriene receptor antagonist therapy in
EoE is inconclusive. Several case series ascribe therapeutic
benefits to the application of leukotriene receptor antago-
nists in EoE patients [75–77]. On the other hand,
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leukotriene receptor antagonists have also been reported to
be ineffective in EoE [78] or only effective in a patient sub-
set [79]. At this point, it is tempting to speculate that the
definition of an EoE patient subpopulation that is defined
by LTC4S mRNA levels might be a first step to identify in-
dividuals that benefit most from treatment with leukotriene
receptor antagonists.
Another EoE subgroup is defined by low transcript
levels of LTC4S but elevated IL23 transcripts (referred
to as IL23-EoE, [74]). IL23 is considered to be associated
with Th17 immune responses [80], such as in a severe
type of asthma [81–83]. The IL23-EoE phenotype might
thus have a more pronounced Th17 phenotype. The lat-
ter finding would be in line with the concept that EoE
can be a manifestation of asthma in the esophagus [84].
Defining such a subgroup might have significant conse-
quences on patient management since asthma treatment
strategies could be considered.
In an independent study, we described another EoE
subtype that is associated with an increased CD1d-
restricted, invariant chain natural killer T (iNKT) cell
compartment (referred to as iNKT-EoE, [73]). Jyonouchi
et al. also discusses the role of iNKT cells in EoE,
explaining that an iNKT cell-mediated Th2-type cyto-
kine response can lead to allergic inflammation in EoE
[85]. Our study found iNKT-EoE to be an early-onset
form of EoE, predominantly present in children under
six years of age. Interestingly, LTC4S-EoE and iNKT-
EoE have overlapping features as these subgroups ap-
peared to present with more food allergy and higher
levels of serum IgE. Further subgroup analysis implied
that iNKT-EoE patients fall rather uniformly into the
LTC4S-EoE group, as these patients also express high
levels of LTC4S, suggesting that iNKT-EoE might be a
subentity of LTC4S-EoE. This topic deserves integration
into the growing discussions about EoE and classical
food allergy [86].
The distribution analysis of mRNA expression levels of
the mast cell marker carboxypeptidase3 [72, 74] also
supports the existence of a subpopulation of MC-EoE
patients. Rothenberg and colleagues recently published
that in EoE patients, mast cells are associated with dys-
phagia [87]. In experimental murine EoE, mast cells have
been shown to play a role in muscular cell hyperplasia
[88]. In addition, it has been suggested that mast cells
modulate esophageal contraction by increasing smooth
muscle contractility, which could underlie dysphagia
[89]. In summary, the precise role of mast cells in EoE
warrants further investigation.
Experimental murine eosinophilic esophagitis
Defining clinical subtypes in EoE patients is a first essen-
tial step towards establishing novel treatment strategies
that take individual variations of the EoE pathology into
account. Going forward, human cohorts might be less
useful here because mechanistic studies are hardly feas-
ible in patients.
One perfect example for the problem of doing func-
tional studies that define cause and effect in EoE path-
ology are studies on the role of the microbial signals for
EoE development. Such studies are highly important in
view of the recent description of the EoE specific micro-
biome [90] and the rapidly growing knowledge of the role
of microbial signals in allergies of the GI tract [91, 92].
Germ-free humans do not exist and, even in mice, micro-
biome studies are challenging and highly costly. Irrespec-
tively, the use of germ-free murine models provides us
with unique opportunities to study the impact of individ-
ual microbial strains on the pathology of EoE.
Commonly used strategies to model EoE in mice
Experimental strategies to understand pathophysiologic
differences of EoE as seen in patients require murine
disease models that phenocopy human EoE and its sub-
types in vivo as closely as possible. Using a variety of al-
lergens, diverse types of sensitization, and different types
of challenges, several murine models of experimental
EoE have been described in the literature. For a conclu-
sive review on the established experimental models of
EoE, we refer to Mishra et al [93].
The most commonly used experimental EoE model uses
intranasal application of Aspergillus in a sensitization/
challenge type of model [93, 94]. The esophageal infiltrate
in this model contains mast cells. Therefore, the Aspergil-
lus model might be well suited to study MC-EoE. Since
Aspergillus is also a common antigen in asthma, this strat-
egy could also be useful for studying subtypes of EoE that
are associated with asthma. In contrast, the combination
of peanut antigen and sensitization with aluminum hy-
droxide as adjuvant (PA/alum) has been established for in-
ducing iNKT cell infiltration in EoE [93, 94]. It is therefore
likely that the latter model is best suited to study iNKT-
EoE. Presently, no reports on age-dependency of murine
EoE models are found in the literature, whereas age-
dependency and a role of the microbial signals early in life
have been demonstrated for the development of allergic
asthma [95].
Using humanized mice to study mucosal allergy –
implications for eosinophilic esophagitis
Following the established concept that EoE is, at least in a
considerable number of patients, a manifestation of an IgE-
mediated allergy, one has to consider that experimental
murine EoE needs to be studied in models that faithfully
mimic the human IgE network [96]. Importantly, a direct
comparison of the murine and human IgE Fc receptor
expression profile during the in situ characterization of IgE-
binding structures of the human esophagus [97] revealed a
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substantial shortcoming of murine models of EoE. We
found that FcεRI, the high affinity IgE Fc receptor [96, 98],
was the only IgE receptor that was robustly expressed in
the esophageal tissue of patients with EoE (Fig. 1 and [97]).
Dendritic cells (DCs) and mast cells were the predominant
FcεRI expressing cells, while eosinophils hardly expressed
FcεRI in the esophagus of EoE patients [97]. Comparative
mRNA pattern analysis showed that more DCs and, there-
fore, also more DC-bound IgE is found in the non-inflamed
esophagus than in EoE [72, 73, 97]. Additionally, we found
that FcεRI on DCs critically contributes to the cell-bound
fraction of the human IgE pool in peripheral blood of EoE
patients [97, 99, 100]. In mice, however, DCs do not consti-
tutively express FcεRI and, therefore, cannot form a DC-
bound IgE pool in tissue or blood [101, 102]. For a sum-
mary of the constitutive expression of FcεRI in humans, see
Table 1. In conclusion, it is fair to postulate that murine
EoE models fail to faithfully represent the DC-specific frac-
tion of the cell-bound IgE pool as found in EoE patients.
As corroborated by studies from our own laboratory, al-
lergic Th2-type diseases such as EoE are on the list of hu-
man conditions that are not fully modeled by the murine
immune system in their complexity [103]. For many years,
the inconvenient reality of divergences in human and
murine immune responses has prompted investigators to
dedicate active research effort to the humanization of
mice as summarized and discussed recently by Grisham
and colleagues [104]. The use of humanized models in
which immune compromised animals are repopulated
with human cells has proven problematic for allergy re-
search because such animals do not mount proper IgE re-
sponses [104, 105]. Our research group has recently
worked on a humanized model in which animals that lack
murine major histocompatibility complex class II (MHC
II) and instead express human leukocyte antigen DR1
(HLA-DR1) were studied [106]. Importantly, such human-
ized mice presented with robust serum IgE levels indica-
tive of an improved allergy model [106]. However, the
DC-bound IgE pool was not reconstituted in these ani-
mals, which renders this model inappropriate for research
questions that address the role of IgE in EoE (Fiebiger lab,
unpublished observation). As an alternative strategy, our
laboratory has established mouse strains in which a trans-
genic (TG) approach was chosen for the expression of the
Fig. 1 IgE Fc receptor expression of the human esophagus. a Dendritic cells of the esophagus express FcεRI. Anti-FcεRIalpha staining in esophageal tissue.
Left: EoE, right non-inflamed control tissue. b Comparative expression analysis of CD23 and FcεRI in EoE tissue. c Esophageal dendritic cells (CD1a staining)
and esophageal mast cells (C-kit staining). d FcεRI/CD1a immune fluorescence histochemistry of the esophagus. Finding originally published in [97,
99, 100]
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IgE-binding alpha chain using the DC-specific CD11c pro-
moter. DCs of such mice (referred to as IgER-TG mice
[101, 107–109]) express FcεRI and are IgE-loaded like
their human counterparts [101, 102, 107, 108, 110]. It is
important to stress that several of the proposed IgER-TG
strains are characterized in detail and have been published
by our group as well as others.
Research applying IgER-TG mice has provided surpris-
ing insights into the physiological role of FcεRI-bound
IgE in allergy. None of the IgER-TG strains developed a
spontaneous allergic phenotype, implying that the pres-
ence of cell-bound IgE on DCs does not drive the devel-
opment of allergies, including EoE. Using three
independently generated IgER-TG strains on two differ-
ent backgrounds, less severe Th2-type allergic inflamma-
tion was found in the TG animals than in their wild-type
counterparts, which did not have DC-bound IgE. Experi-
ments with human DCs confirmed that IgE-crosslinking
dampens the TLR-ligand-induced production of Th2-
promoting cytokines, validating that experiments in the
IgER-TG mice yield results that are directly relevant for
human allergy [107]. Furthermore, FcεRI on human
monocytes and DCs has been shown to contribute to
IgE clearance [111], substantiating that FcεRI on DCs is
regulatory [101, 102]. How immune regulatory IgE-
mediated signals operate and/or fail in EoE is currently
unknown, and the role of DC-bound IgE in the patho-
physiology of EoE has not been addressed experimen-
tally as of yet. Therefore, we propose that IgER-TG mice
should be used as an improved model for studying
mechanisms that regulate allergic IgE-mediated inflam-
mation in EoE and the development of EoE disease
subtypes.
Conclusions and future perspectives
Cumulative evidences support the existence of subtypes
of EoE. Inflammatory tissue mRNA pattern analysis
might be a feasible approach to define certain EoE
patient subpopulations, but more studies are required to
validate the approach. Currently, the development of ex-
perimental strategies that aim at providing mechanistic
insights into cellular and molecular pathways that regu-
late the development of EoE subtypes are highly import-
ant. New insights into mechanisms responsible for the
manifestation of diverse pathologies are a prerequisite to
establish the concept of different EoE subtypes more
convincingly. Research efforts along this line will lead to
improved understanding of causative triggers for EoE, in
general, and more specifically of factors that define indi-
vidual EoE subtypes. A better understanding of diverse
EoE pathologies, in turn, has the potential to direct the
development of new therapeutic approaches with a focus
on individualized patient therapy.
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Human FcεRI Murine FcεRI
Cell type
Mast cell αβγ2 αβγ2
Basophils αβγ2 αβγ2
Dendritic cells αγ2 –
Eosinophils in tissue αγ2 –
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